Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)
Rociletinib (CO-1686), a 2,4-diaminopyrimidine derivative, is a highly potent tyrosine kinase inhibitor (TKI) that acts on epidermal growth factor receptor (EGFR) with L858R/T790M mutations. We supposed radioiodinated CO-1686 would function as a useful tool for monitoring EGFR L858R/T790M mutations....
Main Authors: | Muammar Fawwaz, Kenji Mishiro, Ryuichi Nishii, Izumi Sawazaki, Kazuhiro Shiba, Seigo Kinuya, Kazuma Ogawa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/12/2914 |
Similar Items
-
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021-03-01) -
Radiotheranostics Coupled between an At-211-Labeled RGD Peptide and the Corresponding Radioiodine-Labeled RGD Peptide
by: Kazuma Ogawa, et al.
Published: (2019-03-01) -
Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
by: Fanpu Zeng, et al.
Published: (2020-05-01) -
Preparation for radioiodine therapy: How to increase therapeutic efficacy and accelerate unbound radioiodine excretion
by: Matović Milovan
Published: (2013-01-01) -
Evaluation of radioiodinated curcumin for its potential as a tumor-targeting radiopharmaceutical
by: Chandan Kumar, et al.
Published: (2016-01-01)